N-[(1R)-1-(1,5-dimethylpyrazol-4-yl)ethyl]-2-[1-(3-fluorophenyl)sulfonylpiperidin-4-yl]acetamide
C20H27FN4O3S — CID 92633777
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[(1R)-1-(1,5-dimethylpyrazol-4-yl)ethyl]-2-[1-(3-fluorophenyl)sulfonylpiperidin-4-yl]acetamide
N-[(1R)-1-(1,5-dimethylpyrazol-4-yl)ethyl]-2-[1-(3-fluorophenyl)sulfonylpiperidin-4-yl]acetamide (PubChem CID 92633777) has the molecular formula C20H27FN4O3S and a molecular weight of 422.53 g/mol. Its IUPAC name is N-[(1R)-1-(1,5-dimethylpyrazol-4-yl)ethyl]-2-[1-(3-fluorophenyl)sulfonylpiperidin-4-yl]acetamide.
Molecular Properties
| Compound Name | N-[(1R)-1-(1,5-dimethylpyrazol-4-yl)ethyl]-2-[1-(3-fluorophenyl)sulfonylpiperidin-4-yl]acetamide |
|---|---|
| PubChem CID | 92633777 |
| Molecular Formula | C20H27FN4O3S |
| Molecular Weight | 422.53 g/mol |
| Exact Mass | 422.18 |
| IUPAC Name | N-[(1R)-1-(1,5-dimethylpyrazol-4-yl)ethyl]-2-[1-(3-fluorophenyl)sulfonylpiperidin-4-yl]acetamide |
| SMILES | Cc1c([C@@H](C)NC(=O)CC2CCN(S(=O)(=O)c3cccc(F)c3)CC2)cnn1C |
| InChI | InChI=1S/C20H27FN4O3S/c1-14(19-13-22-24(3)15(19)2)23-20(26)11-16-7-9-25(10-8-16)29(27,28)18-6-4-5-17(21)12-18/h4-6,12-14,16H,7-11H2,1-3H3,(H,23,26)/t14-/m1/s1 |
| InChIKey | QBCWNQBIHRIFLJ-CQSZACIVSA-N |
| XLogP | 2.54 |
| TPSA | 84.30 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 422.53 |
| LogP ≤ 5 | 2.54 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 92633777 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.